Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial

Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial Publisher

Abbashashemi SA¹ ; Yari Z² ; Hatami B³ ; Anushiravani A⁴ ; Kolahdoozan S⁴ ; Zamanian A¹ ; Akbarzadeh N¹ ; Hekmatdoost A¹

Show Affiliations

1. Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, Iran
2. Department of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3. Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti University of Medical Science, Tehran, Iran
4. Digestive Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran

Source: Heliyon Published:2025

Abstract

Aim: We investigated the possibility of caffeine supplementation for managing the inflammation, and hepatic function in cirrhotic patients. Methods: In this randomized, double-blind, placebo-controlled trial, fifty patients with cirrhosis were randomly assigned to receive either caffeine supplement (400 mg), or placebo for eight weeks. Results: The results indicated a significant decrease in AST, platelets (P = 0.002), and PTT (P < 0.001), in the caffeine group compared to the placebo group. Also, caffeine supplementation resulted in a significant reduction in inflammatory biomarkers compared to placebo (p < 0.05). A significant improvement in liver indices including AST to platelet ratio index (APRI), (P < 0.001). Fibrosis 4 score (P < 0.001), and MELD score (P = 0.034)., was observed after 8 weeks caffeine supplementation. Conclusion: The results of the present study indicated that daily supplementation of 400 mg caffeine in cirrhotic patients can significantly improve liver fibrosis and reduce inflammatory factors. The trial was registered at the Iranian Registry of Clinical Trials (Registration ID: IRCT20100524004010N34). © 2024 The Authors

Related Docs

1. Diet and Upper Gastrointestinal Malignancies, Gastroenterology (2015)

2. Effects of Supplementation With Main Coffee Components Including Caffeine And/Or Chlorogenic Acid on Hepatic, Metabolic, and Inflammatory Indices in Patients With Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes: A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial, Nutrition Journal (2021)

Experts (# of related papers)

View all Related Experts

Mohammad Reza Mohajeri Tehrani (1)

Hossein Poustchi (1)

Style	Citing Format
MLA	Abbashashemi SA, et al.. "Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial." Heliyon, vol. 11, no. 1, 2025, pp. -.
APA	Abbashashemi SA, Yari Z, Hatami B, Anushiravani A, Kolahdoozan S, Zamanian A, Akbarzadeh N, Hekmatdoost A (2025). Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial. Heliyon, 11(1), -.
Chicago	Abbashashemi SA, Yari Z, Hatami B, Anushiravani A, Kolahdoozan S, Zamanian A, Akbarzadeh N, Hekmatdoost A. "Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial." Heliyon 11, no. 1 (2025): -.
Harvard	Abbashashemi SA et al. (2025) 'Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial', Heliyon, 11(1), pp. -.
Vancouver	Abbashashemi SA, Yari Z, Hatami B, Anushiravani A, Kolahdoozan S, Zamanian A, et al.. Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial. Heliyon. 2025;11(1):-.
BibTex	@article{ author = {Abbashashemi SA and Yari Z and Hatami B and Anushiravani A and Kolahdoozan S and Zamanian A and Akbarzadeh N and Hekmatdoost A}, title = {Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial}, journal = {Heliyon}, volume = {11}, number = {1}, pages = {-}, year = {2025} }
RIS	TY - JOUR AU - Abbashashemi SA AU - Yari Z AU - Hatami B AU - Anushiravani A AU - Kolahdoozan S AU - Zamanian A AU - Akbarzadeh N AU - Hekmatdoost A TI - Caffeine Supplement, Inflammation, and Hepatic Function in Cirrhotic Patients: A Randomized, Placebo- Controlled, Clinical Trial JO - Heliyon VL - 11 IS - 1 SP - EP - PY - 2025 ER -

Science Communicator Platform

Authors

Authors Affiliations

Abstract